A meta-analysis using 5 RCT of 147 patients with NAFLD/NASH reported that PTX treatment could reduce body weight, glucose, liver transaminases, and TNF-α level. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.